StockNews.com Initiates Coverage on Bellerophon Therapeutics (NASDAQ:BLPH)

StockNews.com began coverage on shares of Bellerophon Therapeutics (NASDAQ:BLPH) in a research report released on Tuesday. The firm issued a hold rating on the biotechnology company’s stock.

Bellerophon Therapeutics Price Performance

Shares of BLPH opened at $0.04 on Tuesday. The company has a 50 day moving average of $0.04 and a two-hundred day moving average of $0.05. The company has a market cap of $440,388.00, a price-to-earnings ratio of -0.04 and a beta of 0.70. Bellerophon Therapeutics has a twelve month low of $0.03 and a twelve month high of $0.08.

Bellerophon Therapeutics Company Profile

Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension.